Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during
percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on
platelet inhibition in patients presenting with acute coronary syndrome (ACS). Platelet
inhibition following a prasugrel LD in clopidogrel pretreated patients' will be determined in
a time-dependent manner for two different prasugrel loading doses (30 mg and 60 mg).
Understanding the effects of this combination on platelet inhibition will provide guidance to
physicians on the use of prasugrel in patients who have already been pretreated with
clopidogrel.